These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27161974)

  • 21. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ;
    Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
    Sanchez BC; Sundqvist M; Fohlin H; Spyratos F; Nordenskjöld B; Stål O; Linderholm BK
    Eur J Cancer; 2010 Jun; 46(9):1580-7. PubMed ID: 20413297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
    Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
    J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
    Rutqvist LE; Johansson H;
    Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
    Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
    J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
    Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
    Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
    De Placido S; De Laurentiis M; Carlomagno C; Gallo C; Perrone F; Pepe S; Ruggiero A; Marinelli A; Pagliarulo C; Panico L; Pettinato G; Petrella G; Bianco AR
    Clin Cancer Res; 2003 Mar; 9(3):1039-46. PubMed ID: 12631604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.